Search
Ensartinib
go.drugbank.com/drugs/DB14860ApprovedInvestigational[A273968] Chemically, ensartinib is an aminopyridazine-based, small molecule tyrosine kinase inhibitor (TKI) which inhibits the anaplastic lymphoma kinase (ALK) protein. … [A265030] The drug is 10-fold more potent in the inhibition of the growth of ALK-positive lung cancer cell lines when compared to [crizotinib].
Antipyrine
go.drugbank.com/drugs/DB01435ApprovedAn analgesic and antipyretic that has been given by mouth and as ear drops. Antipyrine is often used in testing the effects of other drugs or diseases on drug-metabolizing enzymes in the liver.
L-Glutamine
go.drugbank.com/drugs/DB00130ApprovedInvestigationalNutraceuticalIt is the principal carrier of nitrogen in the body and is an important energy source for many cells. … An oral formulation of L-glutamine was approved by the FDA in July 2017 for use in sickle cell disease [L892]. This oral formulation is marketed under the tradename Endari by Emmaus Medical.
Oxamniquine
go.drugbank.com/drugs/DB01096ApprovedAn anthelmintic with schistosomicidal activity against Schistosoma mansoni, but not against other Schistosoma spp. … Oxamniquine causes worms to shift from the mesenteric veins to the liver where the male worms are retained; the female worms return to the mesentery, but can no longer release eggs.
Bezlotoxumab
go.drugbank.com/drugs/DB13140Approved[L46976] First approved by the FDA on October 21, 2016,[A260106] bezlotoxumab is used to reduce the recurrence of _C. difficile_ infection. … Bezlotoxumab is a fully humanized ImmunoglobulinG1 (IgG1) kappa monoclonal antibody that binds to _Clostridium difficile_ toxin B and neutralizes its effects.
Irofulven
go.drugbank.com/drugs/DB05786InvestigationalMGI-114 (Irofulven) is currently being developed by MGI PHARMA, Inc., an emerging oncology-focused pharmaceutical company based in Minneapolis. … Phase III clinical trials involving the drug have been underway since early 2001 at sites in the U.S. and Europe.
Mycophenolic acid
go.drugbank.com/drugs/DB01024ApprovedInvestigational[A249175] This regimen can be used in place of the older anti-proliferative [azathioprine] due to its stronger immunosuppressive potency. … [A249180,A249185] Mycophenolic acid is available as enteric-coated tablets of delayed-release, in an effort to improve upper gastrointestinal adverse events by delaying mycophenolic acid release until
Nuclear receptor subfamily 0 group B member 1
go.drugbank.com/bio_entities/BE0000074TargetHumansNuclear receptor that lacks a DNA-binding domain and acts as a corepressor that inhibits the transcriptional activity of other nuclear receptors through heterodimeric interactions (PubMed:12482977, PubMed
Polypeptides: Nuclear receptor subfamily 0 group B member 1Synonyms: Nuclear receptor DAX-1Nuclear receptor subfamily 1 group D member 1
go.drugbank.com/bio_entities/BE0009347TargetHumansActs as a receptor for heme which stimulates its interaction with the NCOR1/HDAC3 corepressor complex, enhancing transcriptional repression. … Binds as a monomer to a response element composed of the consensus half-site motif 5'-[A/G]GGTCA-3' preceded by an A/T-rich 5' sequence (RevRE), or as a homodimer to a direct repeat of the core motif spaced
Polypeptides: Nuclear receptor subfamily 1 group D member 1Leucine-rich repeat serine/threonine-protein kinase 2
go.drugbank.com/bio_entities/BE0009457TargetHumansTogether with RAB29, plays a role in the retrograde trafficking pathway for recycling proteins, such as mannose-6-phosphate receptor (M6PR), between lysosomes and the Golgi apparatus in a retromer-dependent
Polypeptides: Leucine-rich repeat serine/threonine-protein kinase 2